Published in AIDS Weekly, February 4th, 2002
Dr. Aftab A. Ansari and colleagues at Emory University School of Medicine in Atlanta assessed the benefits of "recombinant rhesus interleukin-12 (rMamu-IL-12) administration during acute simian immunodeficiency virus SIVmac 251 infection" in their study, published in the February 2002 edition of the Journal of Virology.
High doses of the recombinant cytokine enabled treated animals to survive SIV infection, Ansari and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.